New approach targets lung Cancer's genetic engine
NCT ID NCT06685718
Summary
This early-stage trial is testing a new drug called BG-60366 in people with advanced non-small cell lung cancer that has a specific genetic change called an EGFR mutation. The drug is designed to find and break down the faulty protein that drives this type of cancer. Researchers will first determine a safe dose and then see if the drug can shrink tumors in about 93 participants whose cancer has worsened despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Health
RECRUITINGHeidelberg, Victoria, VIC 3084, Australia
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Blacktown Cancer and Haematology Centre
RECRUITINGBlacktown, New South Wales, NSW 2148, Australia
-
Cancer Research South Australia
RECRUITINGAdelaide, South Australia, SA 5000, Australia
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215-5418, United States
-
Fondazione Irccs San Gerardo Dei Tintori Sc Oncologia
RECRUITINGMonza, 20900, Italy
-
Fondazione Policlinico Universitario Agostino Gemelli
RECRUITINGRoma, 00168, Italy
-
Guangdong Provincial Peoples Hospital Huifu Branch
RECRUITINGGuangzhou, Guangdong, 510120, China
-
H Puerta de Hierro Majadahonda
RECRUITINGMajadahonda, 28222, Spain
-
Harbour Cancer and Wellness
RECRUITINGAuckland, 1023, New Zealand
-
Hospital Universitario Vall Dhebron
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario de Octubre
RECRUITINGMadrid, 28041, Spain
-
Liverpool Hospital
RECRUITINGLiverpool, New South Wales, NSW 2170, Australia
-
Memorial Sloan Kettering Cancer Center Mskcc
RECRUITINGNew York, New York, 10065-6800, United States
-
Ohio State University
RECRUITINGColumbus, Ohio, 43210-1132, United States
-
Peter Maccallum Cancer Centre
RECRUITINGMelbourne, Victoria, VIC 3000, Australia
-
Princess Alexandra Hospital
RECRUITINGWoolloongabba, Queensland, QLD 4102, Australia
-
Samsung Medical Center
RECRUITINGGangnamGu, Seoul Teugbyeolsi, 06351, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, Seoul Teugbyeolsi, 03080, South Korea
-
Severance Hospital Yonsei University Health System
RECRUITINGSeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea
-
Shanxi Bethune Hospital
RECRUITINGTaiyuan, Shanxi, 030032, China
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicineqiantang Branch
RECRUITINGHangzhou, Zhejiang, 310018, China
-
The Second Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, 330006, China
-
The Tumor Hospital Affiliated to Guangxi Medical Universitywuxiang Branch
RECRUITINGNanning, Guangxi, 530201, China
-
The University of Texas Md Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4009, United States
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
-
University of Colorado
RECRUITINGDenver, Colorado, 80202-1702, United States
-
Washington University School of Medicine Siteman Cancer Center
RECRUITINGSt Louis, Missouri, 63110-1032, United States
Conditions
Explore the condition pages connected to this study.